May 8 – 10, 2018

Boston, MA

Day One
Wednesday May 9th, 2018

Day Two
Thursday May 10th, 2018

07.30
Registration & Networking

08.20
Chairs Opening Remarks

Overcoming Challenges for 3D Models in Preclinical Discovery & Assessing of Cytotoxic Effects of Oncology Drug Candidates

08.30
Overcoming Challenges for 3D Models in Preclinical Discovery & Assessing of Cytotoxic Effects of Oncology Drug Candidates

Synopsis

  • Reviewing key aspects of stem cell therapy for brain cancer
  • Demonstrating new models for assessing heterogeneous tumor responses to cell therapies
  • Showcasing new strategies for overcoming tumor heterogeneity developed using new
  • 3D culture and tissue-based systems

09.00
Addressing Development, Validation and Automation of 3D Solid Tumor Models in Preclinical Drug Discovery

  • Jason Ekert Head of Complex In Vitro Models, GlaxoSmithKline

Synopsis

  • Highlighting opportunities and challenges in adoption of 3D solid tumor models in preclinical drug discovery
  • What key components should be considered when developing a 3D solid tumor model that is more physiological relevant?
  • How do we validate, scale and automate 3D solid tumor models in preclinical drug discovery?

09.30
A Comparative Analysis of 3D Platforms in High Throughput Formats to Assess the Cytotoxic Effect of Drugs for Discovery

  • Timothy Spicer Assistant Professor - Molecular Medicine & Associate Scientific Director, Scripps Institute

Synopsis

  • Showcasing a fully automated 1536 well compatible platform able to perform HTS on large compound libraries
  • Highlighting the applicability of 3D spheroid-based uHTS assays for the purpose of testing molecules in a more phenotypically relevant format to cancer biology

10.00
Speed Networking & Morning Refreshments

In Vitro Constitution of Stromal Biology & Humanized TME to Support Anticancer Therapeutics